NVS vs MRK vs LLY Stock Comparison

Novartis Ag, Merck and Eli Lilly Prices as of Nov 13, 2026 Peers: Industry group
NVS Novartis Ag
$160.55 +9.3% 1M +21.7% 1Y
Market cap
$313.98B
P/E
17.9x
Revenue (TTM)
—
Div. yield
–
Pharmaceuticals Healthcare
3 wins
MRK Merck & Co., Inc.
$147.78 +0.3% 1M +59.0% 1Y
Market cap
$364.29B
P/E
148.5x
Revenue (TTM)
$67.38B
Div. yield
0.02%
Pharmaceuticals Healthcare
1 win
LLY ELI LILLY & Co
$1,445.40 +19.4% 1M +41.3% 1Y
Market cap
$1.30T
P/E
47.1x
Revenue (TTM)
$86.46B
Div. yield
–
Pharmaceuticals Healthcare
7 wins

Head to Head

11 decided of 12

Eli Lilly leads on 7 of the 12 questions below (Eli Lilly 7, Novartis Ag 3, Merck 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNVSMRKLLYLeader
Larger companyMarket capitalisation $313.98B $364.29B $1.30T LLY
Cheaper on earningsLower P/E, profitable companies only 17.9x 148.5x 47.1x NVS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.1x 56.6x 43.1x NVS
Faster revenue growthRevenue growth, trailing twelve months — +4.9% +45.5% LLY
More profitableNet margin, trailing twelve months — 3.6% 31.9% LLY
Better return on capitalReturn on invested capital — 2.5% 30.9% LLY
Less leveragedLower net debt / EBITDA — 3.6x 1.2x LLY
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months +21.7% +59.0% +41.3% MRK
Better 5-year returnAnnualised price return, 5 years +14.3%/yr +12.0%/yr +41.0%/yr LLY
Less volatileAnnualised volatility, 1 year 27.8% 29.6% 35.0% NVS
Higher overall scoreMean of the five percentile scores vs peers — 61/100 71/100 LLY

Percentile Scorecard

NVSMRKLLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNVSMRKLLY
Valuation 96 #26 of 660 85 #97 of 660 76 #159 of 660
Growth – 30 #434 of 619 93 #45 of 619
Profitability – 90 #59 of 595 98 #11 of 595
Financial Health – 21 #538 of 683 26 #505 of 683
Shareholder Returns 79 #97 of 459 79 #98 of 459 64 #167 of 459
Overall – 61 71
  • NVS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRK ranked among 695 companies in Pharmaceuticals and Biotechnology
  • LLY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNVSMRKLLYSPY
1 month +9.3%+0.3%+19.4% -2.0%
3 months +6.4%+8.8%+22.5% -2.8%
6 months +8.4%+32.7%+43.8% +2.0%
Year to date +16.5%+40.4%+34.5% +10.6%
1 year +21.7%+59.0%+41.3% +12.2%
3 years +69.2%+44.6%+136.6% +68.1%
3 years, per year +19.2%+13.1%+33.3% +18.9%
5 years +94.6%+75.9%+456.7% +61.4%
5 years, per year +14.3%+12.0%+41.0% +10.1%
10 years +118.5%+131.1%+1,761.0% +248.5%
10 years, per year +8.1%+8.7%+34.0% +13.3%

Risk

MeasureNVSMRKLLYSPY
Volatility, 1Y 27.8%29.6%35.0% 13.6%
Downside volatility, 1Y 30.0%24.1%30.0% 13.9%
Beta vs S&P 500, 1Y 0.360.200.30 1.00
Return / volatility, 1Y 0.781.991.18 0.90
Max drawdown, 5Y -20.4%-44.7%-34.8% -25.4%
From 52-week high -4.8%-5.5%0.0% -3.2%
52-week high $168.62$156.45$1,445.40 $779.14
52-week low $124.36$92.86$851.21 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNVSMRKLLY
P/E now vs peer median 17.9xmedian 17.0x 148.7xmedian 17.0x 46.7xmedian 17.0x
P/S now vs peer median 5.1xmedian 8.4x 5.4xmedian 8.4x 15.7xmedian 8.4x
EV/EBITDA now vs peer median —median 14.6x 33.7xmedian 14.6x 38.0xmedian 14.6x
P/FCF now vs peer median 14.3xmedian 19.0x 24.7xmedian 19.0x 69.2xmedian 19.0x
P/B now vs peer median —median 2.0x 8.1xmedian 2.0x 33.8xmedian 2.0x
PEG now vs peer median —median 0.43 -8.16median 0.43 0.61median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNVSMRKLLY
Revenue – $67.38B $86.46B
Gross profit – $48.35B $72.31B
Operating income – $4.76B $34.77B
Net income – $2.45B $27.58B
Free cash flow – $14.75B $19.66B
R&D – $30.76B $15.38B
EPS (diluted) – $0.99 $30.87
Cash & equivalents $400.00M $9.55B $4.89B
Total debt – $53.78B $49.50B
Shares (diluted) 1.96B 2.48B 893.40M
Enterprise value $287.22B $327.23B $1.27T

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNVSMRKLLY
P/E 17.9x 148.7x 46.7x
P/FCF 14.3x 24.7x 69.2x
P/Operating cash flow – 19.5x 44.4x
P/S 5.1x 5.4x 15.7x
P/B – 8.1x 33.8x
P/Tangible book – 17.8x 61.3x
EV/EBITDA – 33.7x 38.0x
EV/EBIT – 85.8x 40.4x
EV/Revenue – 6.1x 16.2x
EV/FCF – 27.7x 71.4x
EV/Operating cash flow – 21.8x 45.8x
PEG (3Y EPS CAGR) – -8.16 0.61

Growth

14 metrics
MetricNVSMRKLLY
Revenue growth (1Y) – 4.9% 45.5%
Revenue CAGR (3Y) – 4.3% 39.2%
Gross profit growth (1Y) – -2.5% 46.6%
Gross profit CAGR (3Y) – 3.8% 42.0%
Operating income growth (1Y) – -78.2% 48.6%
Operating income CAGR (3Y) – -13.9% -97.0%
Net income growth (1Y) – -87.1% 49.8%
Net income CAGR (3Y) – -19.1% 76.8%
EPS growth (1Y) – -87.0% 50.7%
EPS CAGR (3Y) – -18.2% 77.2%
Operating cash flow growth (1Y) – 9.6% 90.8%
Operating cash flow CAGR (3Y) – 2.9% 70.2%
Free cash flow growth (1Y) – 13.0% 124.7%
Free cash flow CAGR (3Y) – 3.8% 80.6%

Profitability

14 metrics
MetricNVSMRKLLY
Gross margin – 71.8% 83.6%
EBITDA margin – 18.0% 42.7%
Operating margin – 7.1% 40.2%
Pretax margin – 7.1% 40.2%
Net margin – 3.6% 31.9%
FCF margin – 21.9% 22.7%
Operating cash flow margin – 27.8% 35.4%
Return on equity – 5.6% 74.4%
Return on assets – 1.9% 19.0%
Return on invested capital – 2.5% 30.9%
Return on capital employed – 4.6% 35.4%
Asset turnover – 0.5x 0.6x
Cash conversion (OCF / net income) – 7.6x 1.1x
Stock comp / revenue – 1.6% 0.8%

Financial Health

11 metrics
MetricNVSMRKLLY
Debt / assets – 40.5% 33.4%
Debt / equity – 1.2x 1.2x
Net debt / EBITDA – 3.6x 1.2x
Debt / FCF – 3.6x 2.5x
Liabilities / assets – 66.1% 72.8%
Equity / assets – 33.9% 27.2%
Interest coverage – – –
Current ratio – 1.4x 1.4x
Quick ratio – 0.8x 0.6x
Cash ratio – 0.3x 0.1x
Altman Z-score – 3.90 9.43

Shareholder Returns

7 metrics
MetricNVSMRKLLY
Dividend yield 3.0% 2.3% 0.6%
Net buyback yield – 0.8% 0.4%
Shareholder yield 3.0% 3.1% 1.0%
Payout ratio (earnings) – 341.6% –
Payout ratio (FCF) – 56.7% –
Dividend growth (1Y) – 3.2% –
Dividend CAGR (3Y) – 4.4% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNVSMRKLLY
Forward P/E 17.1xFY2026 56.6xFY2026 43.1xFY2026
EPS, next fiscal year $9.38FY2026 $2.61FY2026 $33.54FY2026
EPS growth, next FY +4.5%FY2026 -70.9%FY2026 +38.5%FY2026
EPS growth, the year after +0.9% +228.7% +46.0%
Revenue, next fiscal year $53.97BFY2026 $69.66BFY2026 $87.63BFY2026
Revenue growth, next FY -1.0%FY2026 +7.2%FY2026 +34.4%FY2026
Revenue growth, the year after +19.3% -4.6% +18.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNVSMRKLLY
Held by institutions 7.0% 79.9% 83.7%
Institutions holding 1,610 3,804 4,635
Change in shares held, QoQ -6.0% +2.6% +1.5%
Institutions buying 662 1,844 2,636
Institutions selling 562 1,469 1,472
Buyers to sellers 1.18 1.26 1.79

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NVSMRKLLY
NVS 1.00 0.48 0.47
MRK 0.48 1.00 0.44
LLY 0.47 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NVS, MRK and LLY?

Eli Lilly (LLY) is the largest by market capitalisation: Novartis Ag (NVS) $313.98B, Merck (MRK) $364.29B, Eli Lilly (LLY) $1.30T.

Which stock is cheaper, NVS, MRK and LLY?

Novartis Ag (NVS) trades on the lowest price-to-earnings ratio (Novartis Ag (NVS) 17.9x, Merck (MRK) 148.5x, Eli Lilly (LLY) 47.1x). On next year's consensus earnings, Novartis Ag (NVS) is cheapest (Novartis Ag (NVS) 17.1x, Merck (MRK) 56.6x, Eli Lilly (LLY) 43.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Eli Lilly (LLY) grew revenue fastest over the trailing twelve months: Merck (MRK) +4.9%, Eli Lilly (LLY) +45.5%.

Which company is more profitable?

Eli Lilly (LLY) has the highest net margin (Merck (MRK) 3.6%, Eli Lilly (LLY) 31.9%). On return on invested capital, Eli Lilly (LLY) leads (Merck (MRK) 2.5%, Eli Lilly (LLY) 30.9%).

Which stock has performed better?

Over the past year Merck (MRK) returned the most: Novartis Ag (NVS) +21.7%, Merck (MRK) +59.0%, Eli Lilly (LLY) +41.3%. Over five years, Eli Lilly (LLY) compounded fastest (Novartis Ag (NVS) +14.3%/yr, Merck (MRK) +12.0%/yr, Eli Lilly (LLY) +41.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Novartis Ag (NVS) 0.00%, Merck (MRK) 0.02%, Eli Lilly (LLY) 0.00%. Novartis Ag (NVS) and Eli Lilly (LLY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Novartis Ag (NVS) has been the steadiest (Novartis Ag (NVS) 27.8%, Merck (MRK) 29.6%, Eli Lilly (LLY) 35.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NVS, MRK and LLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Eli Lilly (LLY) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.